# Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

> **NCT02283853** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 156 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** dimethyl fumarate
- **DRUG:** Interferon β-1a

## Key facts

- **NCT ID:** NCT02283853
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-28
- **Primary completion:** 2025-07-08
- **Final completion:** 2025-07-08
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283853, "Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02283853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*